Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias

Bone Marrow Transplantation

Volumn 37, Issue 2, 2006, Pages 143-149

  Bunin, N ^a   Aplenc, R ^a   Grupp, S ^a   Pierson, G ^a   Monos, D ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

CD34+ selection; Leukemias; Peripheral stem cells

Indexed keywords

ACICLOVIR; AMOXICILLIN; CD3 ANTIGEN; CD34 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; GENTAMICIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; TACROLIMUS; THIOTEPA;

ADOLESCENT; ADULT; ANTIGEN DETECTION; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CHILD; CHILD CARE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR SELECTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL INFECTION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MALE; MOUTH DISEASE; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SKIN DISEASE; T CELL DEPLETION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTIGENS, CD3; ANTIGENS, CD34; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DISEASE-FREE SURVIVAL; DONOR SELECTION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LYMPHOCYTE TRANSFUSION; MALE; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; THIOTEPA; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 30944445448     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705211     Document Type: Article

References (48)

1. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza Jr FR, Ringden O et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872-4880.
2. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the societe francaise de greffe de moelle. J Clin Oncol 2000; 18: 537-546.
3. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380-3389.
4. Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 4655-4664.
5. Ottinger H, Beelen D, Schuelen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775-2779.
6. Glass B, Uharek L, Zeis M, Dreger P, Loffler H, Steinmann J et al. Allogeneic peripheral blood progenitor cell transplantation in a murine model: Evidence for an improved graft-versus-leukemia effect. Blood 1997; 90: 1694-1700.
7. Paveletic Z, Joshi S, Pirruccello S, Tarantolo SR, Kollath J, Reed EC et al. Lymphocyte reconstitution after allogeneic blood stem transplantation for hematologic malignancies. Bone Marrow Transplant 1998; 21: 33-41.
8. Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: Long-term results of a randomized study. Blood 2002; 100: 3128-3134.
9. Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: Impact on blood progenitor cell transplantation. Blood 1997; 90: 453-463.
10. Korbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H et al. Allogeneic peripheral blood stem cell transplantation: Peripheralization and yield of donor-derived primitive hematopoietic progenitor cells and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
11. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Besinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term follow-up of a randomized trial. Blood 2002; 100: 415-419.
12. Levine J, Kletzel M, Yanik G, Hutchinson RJ, Koehler M, Neudorf S. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a higher incidence of chronic GVHD. Bone Marrow Transplant 2000; 25: 13-18.
13. Brown RA, Adkins D, Khoury H, Vij R, Goodnough LT. DiPersio JF. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: Graft-versus-host disease and transplant-related mortality. J Clin Oncol 1999; 17: 806-812.
14. Champlin R, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Corneilissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702-3709.
15. Bornhauser M, Platzbecker U, Theuser C, Holig K, Ehninger G. CD34+-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: High risk of graft failure, infection and relapse despite donor lymphocyte add-back. Br J Haematol 2002; 118: 1095-1103.
16. Nakamura R, Bahceci E, Read EJ, Leitman SF, Carter CS, Childs R et al. Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol 2001; 115: 95-104.
17. Ng J, Katovich-Hurley CK, Baxter-Lowe LA, Chopek M, Coppo PA, Hegland J et al. Large-scale oligonucleotide typing for HLA-DRB1/3/4 and HLA-DQB1 is highly accurate, specific, and reliable. Tissue Antigens 1993; 42: 473-479.
18. Noreen HJ, Yu N, Setterholm M, Ohashi M, Baisch J, Endres R et al. Validation of DNA-based HLA-A and HLA-B testing of volunteers for a Bone Marrow Registry through parallel testing with serology. Tissue Antigens 2001; 57: 221-229.
19. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
20. Elmaagacli A, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130-1135.
21. Ringden O, Remberger M, Runde V, Bornhauser M, Blau IW, Basara N et al. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation. Blood 1999; 94: 455-464.
22. Remberger M, Ringden O, Blau IW, Ottinger H, Kremens B, Kiehl MG. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739-1745.
23. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105: 548-551.
24. Garderet L, Labopin M, Gorin NC, Polge E, Fouillard L, Ehninger GE et al. Patients with acute lymphoblastic leukemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplant 2003; 31: 23-29.
25. Champlin R, Passweg J, Zhang M, Rowlings PA, Pelz CJ, Atkinson KA et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities. Blood 2000; 95: 3996-4000.
26. Bunin N, Aplenc R, Leahey A, Magira E, Grupp S, Pierson G et al. Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias. Bone Marrow Transplant 2005; 35: 151-158.
27. Bahceci E, Read E, Leitman S, Childs R, Dunbar C, Young NS et al. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical hematopoietic stem cell transplantation for haematological malignancies. Br J Haematol 2000; 108: 408-414.
28. Zaucha J, Gooley T, Bensinger W, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
29. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C et al. Successful engraftment of T-cell-depleted haploidentical "Three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
30. Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A et al. Megadose transplantation of purified peripheral blood CD34+ progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001; 27: 777-782.
31. Lang P, Handgretinger R, Niethammer D, Schlegel PG, Schumm M, Greil J et al. Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood 2003; 101: 1630-1636.
32. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S et al. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-387.
33. Urbano-Ispizua A, Rozman C, Martinez C, Marin P, Briones J, Rovira M et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 1997; 89: 3967-3973.
34. Urbano-Ispizua A, Carreras E, Marin P, Rovira M, Martinez C, Fernandez-Aviles F et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: Detrimental effect of a high number of donor CD34(+) cells? Blood 2001; 98: 2352-2357.
35. Mohty M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bourhis JH et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003; 17: 869-875.
36. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
37. Madero L, Vicent M, Sevilla J, Prudencio M, Rodriguez F, Diaz MA. Engraftment syndrome in children undergoing autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002; 30: 355-358.
38. Lee C-K, Gingrich R, Hohl R, Ajram K. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant 1995; 16: 175-182.
39. Edenfield W, Moores L, Goodwin G, Lee N. An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose. Bone Marrow Transplant 2000; 25: 405-409.
40. Ravoet C, Feremans W, Husson B, Majois F. Kentos A, Lambermont M et al. Clinical evidence for engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation. Bone Marrow Transplant 1996; 18: 943-947.
41. Cahill R, Spitzer T, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 1996; 18: 177-184.
42. Ho V, Kim H, Hochberg E, Hochberg EP, Cutler C, Lee SJ et al. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant 2004; 34: 987-994.
43. Bacigalupo A, Mordini N, Pitto A, Piaggio G, Podesta M, Benvenuto F et al. Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: Severe immunodeficiency and related complications. Brit J Haematol 1997; 98: 760-766.
44. Zaia J, Gallez-Hawkins G, Tegtmeier B, ter Veer A, Li Z, Niland JC et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997; 176: 782-785.
45. Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-763.
46. Eckle T, Prix L, Jahn G, Klingebiel T, Handgretinger R, Selle B et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000; 96: 3286-3289.
47. Eckle T, Lang P, Rix L, Jahn G, Klingebiel T, Handgretinger R et al. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant 2002; 30: 433-439.
48. Appleton A, Sviland L, Peiris J, Taylor CE, Wilkes J, Green MA et al. Human herpes virus-6 infection in marrow graft recipients: Role in pathogenesis of graft-versus-host disease, from the Newcastle upon Tyne Bone Marrow Transplant Group. Bone Marrow Transplant 1995; 16: 777-782.